-
11.发明申请公开(公告)号：US20160304456A1
公开(公告)日：2016-10-20
申请号：US15130603
申请日：2016-04-15
Applicant: Forma Therapeutics, Inc.
Inventor： Pui Yee Ng , Heather Davis , Kenneth W. Bair , Aleksandra Rudnitskaya , Xiaozhang Zheng , Bingsong Han , Nicholas Barczak , David R. Lancia, JR.
IPC: C07D209/96 , C07D401/04 , C07D403/04 , C07D417/06 , C07D491/107 , C07D413/06 , C07D405/06 , C07D405/04 , C07D471/04 , C07D401/06 , C07D403/06
CPC classification number: C07D209/96 , C07D221/20 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/06 , C07D417/06 , C07D471/04 , C07D491/107 , C07D497/10 , C07D519/00
Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6 and HDAC11, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Abstract translation: 本发明涉及组蛋白脱乙酰酶（HDAC）如HDAC6和HDAC11的抑制剂及其在治疗诸如细胞增殖性疾病（例如癌症），神经系统疾病（例如神经变性疾病或神经发育疾病），炎症性疾病 或自身免疫性疾病，感染，代谢疾病，血液病或心血管疾病。
-
![3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2016/08/04/US20160222028A1/abs.jpg.150x150.jpg)
12.发明申请3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 审中-公开3-ALKYL-4-AMIDO-BICYCLIC [4,5,0]氢氧化物作为HDAC抑制剂公开(公告)号：US20160222028A1
公开(公告)日：2016-08-04
申请号：US15013814
申请日：2016-02-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David Lancia, JR. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC: C07D498/04 , C07D267/14 , C07D493/08 , C07D243/14 , C07D495/10 , C07D413/08 , C07D413/14 , C07D413/06 , C07D491/107
CPC classification number: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
Abstract translation: 本公开涉及可用于治疗与HDAC相关的疾病或病症的锌依赖性组蛋白脱乙酰酶（HDAC）的抑制剂，例如具有式I的HDAC6：其中R，L，X 1，X 2，X 3，X 4， Y1，Y2，Y3和Y4。
-
公开(公告)号：US20220185806A1
公开(公告)日：2022-06-16
申请号：US17557215
申请日：2021-12-21
Applicant: FORMA Therapeutics, Inc.
Inventor： Justin Caravella , Bingsong Han , Cuixian Liu , Stephanos Ioannidis , Alexandre Joseph Buckmelter , David James Richard , Matthew W. Martin , Steven Mischke , Scot Mente
IPC: C07D417/12 , C07C261/04 , C07D231/40 , C07D241/04 , C07D265/30 , C07D277/46 , C07D277/56 , C07D417/04
Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.
-
公开(公告)号：US20200079744A1
公开(公告)日：2020-03-12
申请号：US16688469
申请日：2019-11-19
Applicant: FORMA Therapeutics, Inc.
Inventor： Jennifer Lee , Nicholas Barczak , Jaime A. Escobedo , Chiara Conti , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Xiaozhang Zheng
IPC: C07D263/58 , A61P35/00 , A61K31/403 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/435 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/4709 , A61K31/4985 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07C53/06 , C07D209/40 , C07D209/54 , C07D221/20 , C07D235/30 , C07D277/82 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D473/00 , C07D487/04 , C07D491/056 , C07D491/107 , C07D498/04
Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
-
![3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/12/24/US10513501B2/abs.jpg.150x150.jpg)
公开(公告)号：US10513501B2
公开(公告)日：2019-12-24
申请号：US16218122
申请日：2018-12-12
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin , Kenneth W. Bair
IPC: A61K31/513 , C07D243/14 , C07D401/06 , C07D403/06 , C07D401/10 , C07D403/10 , C07D413/06 , C07D417/06 , C07D267/14 , C07D413/12 , C07D413/04 , C07D291/08 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
Patent Agency Ranking
![3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/11/05/US10464910B2/abs.jpg.150x150.jpg)
公开(公告)号：US10464910B2
公开(公告)日：2019-11-05
申请号：US16219669
申请日：2018-12-13
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David R. Lancia, Jr. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC: A61K31/5513 , C07D243/14 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/10/22/US10450284B2/abs.jpg.150x150.jpg)
公开(公告)号：US10450284B2
公开(公告)日：2019-10-22
申请号：US16220041
申请日：2018-12-14
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin
IPC: A61K31/553 , C07D498/04 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/09/24/US10421732B2/abs.jpg.150x150.jpg)
公开(公告)号：US10421732B2
公开(公告)日：2019-09-24
申请号：US16219685
申请日：2018-12-13
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David R. Lancia, Jr. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC: A61K31/553 , C07D267/14 , C07D413/12 , C07D267/12 , C07D413/06 , C07D401/06 , C07D417/04 , C07D471/04 , C07D498/04 , C07D243/14 , C07D291/08 , C07D498/08 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D495/10 , C07D491/107 , C07D413/08 , C07D493/08 , C07D413/04
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2019/04/25/US20190119235A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190119235A1
公开(公告)日：2019-04-25
申请号：US16222871
申请日：2018-12-17
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , David S. Millan , Matthew W. Martin
IPC: C07D267/14 , C07D267/12 , C07D413/04 , C07D413/08 , C07D491/107 , C07D495/10 , C07D413/14 , C07D405/06 , C07D403/10 , C07D403/06 , C07D401/10 , C07D498/08 , C07D291/08 , C07D243/14 , C07D498/04 , C07D471/04 , C07D417/04 , C07D401/06 , C07D413/06 , C07D413/12 , C07D493/08
Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
![3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS](/abs-image/US/2019/04/25/US20190119230A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190119230A1
公开(公告)日：2019-04-25
申请号：US16219685
申请日：2018-12-13
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC: C07D267/14 , C07D413/04 , C07D267/12 , C07D413/06 , C07D401/06 , C07D417/04 , C07D471/04 , C07D498/04 , C07D243/14 , C07D291/08 , C07D498/08 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D495/10 , C07D491/107 , C07D413/08 , C07D493/08 , C07D413/12
CPC classification number: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
-
-
-
-
-
-
-
-
Search Results
73
records
(took 0.204 seconds)
